Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SIOG 2017 /
Bevacizumab and colorectal cancer in geriatrics

9th - 11th Nov 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 16.11.17
Views: 1128

Thomas Aparicio - Hôpital Saint-Louis, Paris, France

Thomas Aparicio talks to ecancer at SIOG 2017 in Warsaw.

He discusses elderly patients with colorectal cancer and the best treatments. 

Dr Aparicio the trails with bevacizumab, and the successes and concerns of this therapy. 

One of these issues is some cardiovascular toxicity, but he says it is manageable. 

He believes that in colorectal cancer, there is not much difference between treating patients who are young and those up to 75. 

This service has been kindly supported by an unrestricted grant from Janssen Oncology.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation